<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-12-12">12 December 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Jürgen</forename><surname>Braun</surname></persName>
							<email>j.braun@rheumazentrumruhrgebiet.de</email>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Ruhr-University Bochum</orgName>
								<address>
									<addrLine>Rheumazentrum Ruhrgebiet</addrLine>
									<settlement>Herne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xenofon</forename><surname>Baraliakos</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Ruhr-University Bochum</orgName>
								<address>
									<addrLine>Rheumazentrum Ruhrgebiet</addrLine>
									<settlement>Herne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Atul</forename><surname>Deodhar</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Division of Arthritis/Rheumatic Diseases (OPO9)</orgName>
								<orgName type="institution">Oregon Health &amp; Science University</orgName>
								<address>
									<settlement>Portland</settlement>
									<region>Oregon</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominique</forename><surname>Baeten</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Clinical Immunology and Rheumatology</orgName>
								<orgName type="department" key="dep2">Academic Medical Center</orgName>
								<orgName type="institution">University of Amsterdam</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joachim</forename><surname>Sieper</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Emery</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution" key="instit2">University of Leeds</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aimee</forename><surname>Readie</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Immunology and Dermatology</orgName>
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<settlement>East Hanover</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruvie</forename><surname>Martin</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Immunology and Dermatology</orgName>
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<settlement>East Hanover</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shephard</forename><surname>Mpofu</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Immunology and Dermatology</orgName>
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hanno</forename><forename type="middle">B</forename><surname>Richards</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Rheumazentrum Ruhrgebiet</orgName>
								<address>
									<addrLine>Claudiusstr. 45</addrLine>
									<postCode>44649</postCode>
									<settlement>Herne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-12-12">12 December 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">7B1828DED87612C8AD947E7D22AACAF0</idno>
					<idno type="DOI">10.1136/annrheumdis-2016-209730</idno>
					<note type="submission">Received 18 April 2016 Revised 18 November 2016 Accepted 20 November 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS).</s><s>Methods In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122).</s><s>Placebotreated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16.</s><s>Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104.</s><s>Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).</s><s>Results 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104.</s><s>In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively.</s><s>Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53.</s><s>Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively.</s><s>Conclusions Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings.</s><s>Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies.</s><s>Trial registration number NCT01358175.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>2]<ref type="bibr" target="#b3">[3]</ref> Long-term treatment goals are to maximise quality of life through control of signs and symptoms, prevention of structural damage and preservation of physical function. <ref type="bibr" target="#b4">4</ref></s><s>]<ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> However, up to 40% of patients do not respond to or cannot tolerate TNF inhibitors, <ref type="bibr" target="#b11">11</ref> and loss of efficacy can occur over time. <ref type="bibr" target="#b12">12</ref></s><s>8]<ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref><ref type="bibr" target="#b23">[23]</ref><ref type="bibr" target="#b24">[24]</ref><ref type="bibr" target="#b25">[25]</ref><ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b28">[27]</ref><ref type="bibr" target="#b29">[28]</ref><ref type="bibr" target="#b30">[29]</ref> In placebo-controlled phase III studies, secukinumab, a fully human anti-IL-17A monoclonal antibody, significantly improved the signs and symptoms of psoriasis, <ref type="bibr" target="#b31">30</ref> psoriatic arthritis (PsA), <ref type="bibr" target="#b32">31</ref> and AS. <ref type="bibr" target="#b33">32</ref></s><s>ere, we present an update on the efficacy and safety of secukinumab in patients with AS during the non-controlled continuation phase of MEASURE 1 (NCT01358175) through 2 years.</s><s>Results of exploratory radiographic endpoints at 2 years are also presented.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and patients</head><p><s>Study design and patient eligibility criteria have been described previously. <ref type="bibr" target="#b33">32</ref></s><s>Briefly, patients were ≥18 years of age, with AS fulfilling the modified New York Criteria, and active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4 <ref type="bibr" target="#b34">33</ref> and a spinal pain score of ≥4 cm on a visual analogue scale (0-10 cm), despite treatment with maximal tolerated doses of NSAIDs.</s><s>Patients who previously received one anti-TNF agent could enrol if they had an inadequate response or had stopped treatment for safety or tolerability reasons (anti-TNF-IR).</s><s>Patients could continue on stable doses of sulfasalazine, methotrexate, prednisone and NSAIDs.</s><s>Key exclusion criteria are detailed in the online supplementary materials.</s></p><p><s>Between 9 November 2011 and 21 January 2013, eligible patients were randomly assigned (1:1:1) to one of two secukinumab arms or placebo (randomisation procedures are described in the online supplementary materials).</s><s>Patients randomised to secukinumab received a 10 mg/kg intravenous infusion at baseline and weeks 2 and 4, followed by subcutaneous injections of 150 mg (secukinumab intravenous 150 mg) or 75 mg (intravenous 75 mg) every four weeks from week 8; patients in the placebo group were treated using the same intravenous-to-subcutaneous schedule.</s><s>Placebo-treated patients were randomly reassigned (1:1) to receive secukinumab 150 or 75 mg subcutaneous every four weeks from week 16 (non-responders) or week 24 (responders), with response based on Assessment of SpondyloArthritis international Society 20 (ASAS20) response criteria. <ref type="bibr" target="#b3">3</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedures and end points</head><p><s>Disease activity and efficacy assessments <ref type="bibr">3 34 35</ref> were conducted at baseline and throughout the study, with key assessments at weeks 16 and 52 (as previously reported), <ref type="bibr" target="#b33">32</ref> and week 104; further details are provided in the online supplementary materials.</s></p><p><s>Lateral view radiographs of the cervical and lumbar spine were obtained at baseline and week 104.</s><s>Images were digitised centrally and patient identifiers and temporal indicators removed to ensure blinding.</s><s>Radiographs were scored using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) method (total score range: 0-72; see online supplementary materials for further details). <ref type="bibr">36 37</ref></s><s>Scoring was conducted by two central, independent readers, blinded with regard to treatment group and temporal sequence, who both read each film; statistical analyses used the mean score from the two readers.</s><s>The top 5% of cases with the highest between-reader differences for change in radiographic score were identified for adjudication, with the two readers performing a third consensus read.</s><s>Data from X-ray completers (patients with X-rays at both baseline and week 104) are presented as mean change from baseline to week 104.</s></p><p><s>Safety analyses assessed adverse events (AEs), serious AEs and routine laboratory values.</s><s>Biochemical investigations were classified according to the Common Terminology Criteria for Adverse Events (V.4.03). <ref type="bibr" target="#b39">38</ref></s><s>Blood samples were collected at baseline through week 104 for assessment of secukinumab immunogenicity using a MesoScale Discovery bridging immunoassay. <ref type="bibr" target="#b40">39</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Clinical efficacy analyses at week 104 were carried out on data from patients originally randomised to secukinumab.</s><s>Statistical analyses for binary variables up to week 104 used multiple imputation to account for missing data, while mixed-effect model repeated measures, with missing data assumed missing at random, were used for continuous variables (except highsensitivity C-reactive protein (hsCRP) was reported as observed).</s><s>Data are also reported 'as observed' among patients with evaluable data.</s><s>Radiographic analyses were assessed in X-ray completers who were initially randomised to secukinumab treatment, and in X-ray completers who switched from placebo to secukinumab at week 16 or 24 ( placebo switchers).</s><s>In each population, data were pooled between treatment groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS Patients</head><p><s>Of 371 patients originally randomised to treatment, 97/125 (77.6%) patients in the secukinumab intravenous 150 mg group, 103/124 (83.1%) in the intravenous 75 mg group and 90/122 (73.8%) in the placebo group (no placebo given beyond week 24) completed week 104.</s><s>AEs (6.4% of patients), lack of efficacy (4.4%) and patient/guardian decision (5.8%) were the main reasons for discontinuation among secukinumab-treated patients (see online supplementary figure <ref type="figure" target="#fig_0">S1</ref>).</s></p><p><s>Demographic and baseline characteristics have been reported previously. <ref type="bibr" target="#b33">32</ref></s><s>Mean time since diagnosis in the three randomised groups was 6.5-8.3 years, mean total BASDAI scores were 6.1-6.5 and median hsCRP levels were 7.4-9.2</s><s>mg/L.</s><s>Approximately 73% of patients were anti-TNF-naive.</s></p><p><s>Concomitant medications through 104 weeks were very similar to 52 weeks and baseline, and included sulfasalazine (35.0%), methotrexate (15.8%), systemic glucocorticoids (19.7%) and NSAIDs (93.6%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical efficacy</head><p><s>Among patients who continued on secukinumab treatment, ASAS20 and ASAS40 response rates similar to those achieved at weeks 16 and 52 <ref type="bibr" target="#b33">32</ref> were observed at week 104 (figure <ref type="figure" target="#fig_0">1A, B</ref>).</s><s>ASAS20/40 response rates at week 104 (with multiple imputation of missing values) were 73.7/55.7%,</s><s>respectively, in the secukinumab intravenous 150 mg group and 68.0/48.5% in the intravenous 75 mg group (table 1).</s><s>Response rates using observed data are reported in table 1. Improvements consistent with those reported previously at weeks 16 and 52 <ref type="bibr" target="#b33">32</ref> were also observed in total BASDAI score (figure <ref type="figure" target="#fig_0">1C</ref>) and all other secondary end points at week 104 (table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>In prespecified subgroup analyses, ASAS20 and ASAS40 response rates in both anti-TNF-naive and anti-TNF-IR patients were higher with secukinumab than placebo at week 16 (see online supplementary figure <ref type="figure">S2</ref>).</s><s>Observed data showed that 59/69 (85.5%) and 47/65 (72.3%) anti-TNF-naive patients in the secukinumab intravenous 150 mg and intravenous 75 mg groups, respectively, achieved an ASAS20 response at week 104; an ASAS40 response was achieved by 48/69 (69.6%) and 34/65 (52.3%) patients, respectively.</s><s>In anti-TNF-IR patients, 10/18 (55.6%) and 15/21 (71.4%) patients achieved an ASAS20 response in the intravenous 150 mg and intravenous 75 mg groups, respectively, while 8/18 (44.4%) and 12/21 (57.1%) patients achieved an ASAS40 response.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Radiographic findings</head><p><s>Of the 97 patients in the secukinumab intravenous 150 mg group and 103 patients in the intravenous 75 mg group who completed week 104, 86 (88.7%) and 82 (79.6%), respectively, had evaluable X-rays at baseline and week 104 (X-ray completers) meeting predefined statistical analysis windows.</s><s>Baseline characteristics of the X-ray completer cohort were similar between dose groups (table <ref type="table" target="#tab_1">2</ref>) and to those previously reported in the overall population. <ref type="bibr" target="#b33">32</ref></s><s>Overall, 104 (61.9%)</s><s>X-ray completers had syndesmophytes at baseline and 105 (62.5%) had hsCRP &gt;5 mg/ L. Baseline characteristics of the 89 placebo-switcher X-ray completers (see online supplementary table <ref type="table" target="#tab_0">S1</ref>) were similar to those originally randomised to secukinumab.</s></p><p><s>Figure <ref type="figure">2</ref> shows the cumulative probability plot for change from baseline in mSASSS at week 104 among X-ray completers randomised to secukinumab at baseline.</s><s>The change in mSASSS (mean±SD) over 104 weeks was 0.30±2.53 in the pooled secukinumab group, 0.30±1.94 in the intravenous 150 mg group and 0.31±3.04 in the intravenous 75 mg group (table <ref type="table" target="#tab_3">3</ref>).</s><s>Changes among placebo switchers were 0.54±2.45</s><s>( pooled), 0.44±2.09</s><s>(150 mg) and 0.64±2.79</s><s>(75 mg) (see online supplementary table <ref type="table" target="#tab_1">S2</ref> and figure <ref type="figure">S3</ref>).</s><s>The smallest detectable change (SDC) was 1.838 and 2.814 at an 80% and 95% level of agreement, respectively.</s><s>As defined by SDC at the 80% level of agreement, a large proportion of patients (&gt;80%) had no spinal radiographic progression.</s><s>The Bland-Altman plot in online supplementary figure S4 shows the level of agreement between the two readers; variability was observed, particularly when an mSASSS change of &gt;0 was recorded.</s><s>The intraclass correlation coefficient (ICC) score for agreement between readers was 0.570 for change in mSASSS.</s></p><p><s>Baseline mSASSS was higher among patients with known predictors of radiographic progression compared with those without (table <ref type="table" target="#tab_3">3</ref>).</s><s>Mean mSASSS change at week 104 among X-ray completers randomised to secukinumab was higher in males than females, in those with baseline syndesmophytes versus those without, in patients with elevated versus normal baseline hsCRP levels and in smokers versus non-smokers (table <ref type="table" target="#tab_3">3</ref>).</s><s>Among the X-ray completers who had no syndesmophytes at baseline and who were randomised to secukinumab, 61/64 (95.3%), remained free from syndesmophytes at week 104.</s><s>Of the 104 X-ray completers with syndesmophytes at baseline, approximately 70% did not develop additional syndesmophytes through week 104 (see online supplementary table <ref type="table" target="#tab_3">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The most common AEs with secukinumab were nasopharyngitis, diarrhoea, headache, upper respiratory tract infections and pharyngitis (table <ref type="table" target="#tab_2">4</ref>).</s><s>Discontinuations due to AEs were infrequent.</s><s>The incidence of serious AEs was low, and similar between the two secukinumab groups (table 4; see online supplementary table <ref type="table" target="#tab_2">S4</ref>).</s></p><p><s>One death was reported among secukinumab-treated patients throughout the study; on day 706, a patient in the intravenous 75 mg group with a history of arterial hypertension and smoking died due to acute respiratory failure secondary to cardiac failure and pulmonary fibrosis.</s><s>No suicides or suicidality-related AEs were reported among secukinumabtreated patients.</s></p><p><s>Candida infections were reported in four secukinumabtreated patients (0.7 cases per 100 patient-years of secukinumab exposure); two oral candidiasis (one in each dose group), one cutaneous Candida infection (150 mg group) and one genital candidiasis (75 mg group).</s><s>All four events were considered mild and non-serious, resolved spontaneously or with standard antifungal therapy, and did not result in study discontinuation.</s><s>Herpes viral infectionsmainly oral herpes and herpes zoster infectionswere reported by 8.3% of patients in the 150 mg group and 2.2% in the 75 mg group.</s><s>All cases were non-serious.</s><s>One led to treatment discontinuation (herpes zoster infection in the 150 mg group).</s></p><p><s>Grade 3 neutropenia occurred at a single visit in each of three patients receiving secukinumab 75 mg and one receiving secukinumab 150 mg.</s><s>Grade 4 neutropenia was reported in one patient (75 mg group) at a single visit.</s><s>None of these events led to treatment interruption or discontinuation.</s><s>One grade 3 case was associated with a non-serious upper respiratory tract infection.</s></p><p><s>Crohn's disease was reported as a non-serious AE in four patients in the 75 mg group (of whom two had a history of Crohn's disease and one a history of a polyp and colon adenoma) and one patient in the 150 mg group, equivalent to 0.8 cases per 100 patient-years of secukinumab exposure.</s><s>Two patients (one in each group; one with a history of Crohn's disease) discontinued because of an AE of Crohn's disease.</s><s>A history of uveitis was reported in 62 (16.7%) patients at baseline.</s><s>An AE of uveitis was reported in 12 patients (seven with history of uveitis) on secukinumab, equivalent to 2.0 cases per 100 patient-years of secukinumab exposure.</s><s>One was a serious AE (150 mg group); this resolved and did not require discontinuation of study treatment.</s><s>Nineteen (5.1%) patients had a history of psoriasis.</s><s>Five patients reported an AE of psoriasis during the study (two on 75 mg, three on 150 mg), Four secukinumab-treated patients (two in each dose group) had cardiovascular events adjudicated as meeting major adverse cardiac event (MACE) criteria: three myocardial infarctions and one ischaemic stroke (see online supplementary table <ref type="table">S5</ref>).</s><s>None of these events led to treatment discontinuation.</s><s>The incidence of MACE was 0.6 per 100 patient-years of secukinumab exposure.</s></p><p><s>Four cases of malignant/unspecified tumours were reported (0.6 per 100 patient-years of secukinumab exposure), all before week 52, and have been described previously. <ref type="bibr" target="#b33">32</ref></s><s>reatment-emergent anti-secukinumab antibodies were detected through week 104 in two patients in the secukinumab 150 mg group; no neutralising antibodies were detected and neither patient experienced a loss of ASAS20 response.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>This analysis demonstrates that secukinumab improves the clinical signs and symptoms of AS through 2 years of continued therapy.</s><s>Secukinumab was effective in both anti-TNF-naive and anti-TNF-IR patients, although absolute response rates were generally higher in anti-TNF-naive patients.</s><s>In contrast to the anti-TNF-naive subgroup, ASAS20 and ASAS40 response rates were highest with secukinumab intravenous 75 mg in anti-TNF-IR patients.</s><s>However, these results should be viewed in the context of the relatively small number of anti-TNF-IR patients, particularly at week 104, and the heterogeneity of this subpopulation, which comprised patients who failed anti-TNF treatment for any one of several reasons, including lack of primary or secondary efficacy, or intolerance.</s><s>Overall, given the lack of therapeutic alternatives, these findings indicate that secukinumab may address an unmet clinical need in  anti-TNF-IR patients, as well as providing a high level of efficacy as first-line therapy in anti-TNF-naive patients.</s><s>Prevention of structural damage is a long-term treatment goal in AS.</s><s>The effect of anti-TNFs on radiographic progression in AS is unclear.</s><s>5]<ref type="bibr" target="#b16">[16]</ref> Authors concluded that the results do not provide evidence that anti-TNF therapy inhibits radiographic progression over 2 years.</s><s>More recent studies have suggested that longer-term (approximately 8 years) treatment with an anti-TNF or earlier treatment initiation may be required to demonstrate an effect on radiographic progression. <ref type="bibr">40 41</ref></s><s>In the present study, the mean change in mSASSS through 2 years of secukinumab therapy was 0.30 (SD 2.53) overall, and 0.38-0.52</s><s>among patients with known predictors of radiographic progression at baseline, such as syndesmophytes or elevated CRP. <ref type="bibr" target="#b43">42</ref></s><s>Comparisons between these findings and those reported in the aforementioned studies and historical cohorts cannot be made because of differences in study designs and populations.</s><s>Data from OASIS are from a period when treatment options were limited, and early TNF inhibitor trials are likely to have had more severe disease than those enrolled in MEASURE 1 and other recent placebocontrolled trials.</s><s>Indeed, patients with evidence of radiographic progression are now more likely to be prescribed an approved TNF inhibitor than enter a clinical trial in which they might be randomised to placebo, and the anti-TNF trials included patients with longer disease duration (∼10-11 years vs ∼7 years in X-ray completers) <ref type="bibr">8 14-16</ref> and more severe radiographic disease at baseline (mSASSS ∼16-20 <ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref> vs ∼10) than in our study.</s><s>Agreement between readers in mSASSS change was modest, with an ICC within the expected range of those reported from other studies. <ref type="bibr">13-15 43</ref></s><s>The Bland-Altman plot indicates that there is inter-reader variability, particularly where changes in mSASSS have occurred.</s><s>The low overall rate of progression seen with secukinumab requires further exploration in long-term controlled studies before definite conclusions can be reached on whether anti-IL-17A therapy is effective in inhibiting mSASSS progression in patients with AS.</s><s>Comparing radiographic changes associated with secukinumab with the historical cohorts, matched in terms of baseline disease, is also a possible area of future research.</s></p><p><s>Secukinumab showed an acceptable safety profile over 622.5 patient-years of exposure, with no new safety signals or unexpected safety findings compared with the first 52 weeks <ref type="bibr" target="#b33">32</ref> or with the safety profile reported in PsA and psoriasis. <ref type="bibr">30 31</ref></s><s>The incidence of AEs was higher with 150 mg than with 75 mg, driven primarily by non-serious infections.</s><s>Serious infections were infrequent in both secukinumab groups.</s><s>Candida infections, a known risk with IL-17 inhibitors given the role of IL-17 in mucosal defence, <ref type="bibr" target="#b46">44</ref> were infrequent, mild and clinically manageable with antifungals.</s><s>No dose dependence was observed for other safety risks.</s><s>All four patients who reported MACE events on secukinumab treatment had pre-existing cardiovascular risk factors.</s><s>The incidence of MACE in our study (0.6 per 100 patient-years) is consistent with reported data in AS. <ref type="bibr" target="#b47">45</ref> Spondyloarthritis is often associated with extra-articular manifestations such as uveitis, psoriasis and inflammatory bowel disease. <ref type="bibr" target="#b2">2</ref> Patients with previous or stable presentation of these conditions could enrol in MEASURE 1.</s><s>The incidence of extraarticular manifestations reported as AEs in our study was low and consistent with expected rates in AS.</s><s>IL-17A has been reported to have either a pathogenic or a protective role in Crohn's disease. <ref type="bibr">46 47</ref></s><s>The incidence of Crohn's disease in the present study (0.8 per 100 patient-years of secukinumab exposure) compares with reported rates of 0.2-1.3 per 100 patientyears for TNF inhibitors in the AS population. <ref type="bibr" target="#b50">48</ref></s><s>imitations of this analysis include the lack of comparator group beyond week 16, limiting interpretation of long-term findings to a comparison between secukinumab doses and to longitudinal evaluation.</s><s>Despite the use of accepted statistical methods to account for missing data during the continuation period of the study, there remains a possible bias from the fact that patients who stay on study are those who do well on study treatment.</s><s>Nevertheless, retention rates were high throughout the study and only 4.4% of patients withdrew because of lack of efficacy during the 2-year period.</s><s>The slow nature of radiographic disease progression in AS means long follow-up periods are required to show measureable changes.</s><s>This prohibits the inclusion of a placebo comparator and can introduce confounding effects of concomitant treatment with other drugs that influence radiographic progression. <ref type="bibr" target="#b51">49</ref></s><s>Although blinded to treatment groups and sequence, readers were aware that all patients received secukinumab, possibly introducing an observational bias.</s></p><p><s>In conclusion, these longitudinal results from MEASURE 1 demonstrate that secukinumab provides similar levels of improvement in the clinical signs and symptoms of AS at 2 years as those previously reported during the short-term placebo-controlled period and provide the first uncontrolled Figure <ref type="figure">2</ref> Cumulative probability plot for change from baseline in the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) at week 104 in X-ray completers randomised at baseline to secukinumab (observed data).</s><s>X-ray completers are those patients with X-rays at both baseline and at week 104.</s><s>Patients received a 10 mg/kg loading dose of secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of secukinumab subcutaneously every four weeks from week 8.  n indicates number of patients with evaluable paired X-ray data at both baseline and week 104 (X-ray completers).</s><s>Data shown as mean (SD).</s><s>mSASSS ranges from 0 to 72, with higher scores indicating greater radiographic damage.</s><s>Patients received 10 mg/kg secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of secukinumab subcutaneously every four weeks from week 8. hsCRP, high-sensitivity C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Summary of selected clinical efficacy end points through week 104 for patients randomised to secukinumab at baseline.</s><s>Assessment of SpondyloArthritis international Society response criteria (ASAS20) (A) and ASAS40 (B) response rates, and mean change in total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (C) over time to week 104 is shown.</s><s>Multiple imputation applied to handle missing data for ASAS20 and ASAS40, mixed-effects model repeated measures used for BASDAI.</s><s>Patients received a 10 mg/kg loading dose of secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of secukinumab subcutaneously every four weeks from week 8.</s></p></div></figDesc><graphic coords="3,51.25,48.42,228.20,582.69" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,247.29,48.42,305.97,172.40" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Summary of efficacy data at week 104 among patients randomised to secukinumab at baseline Binary variables are reported using multiple imputation (percentage of responders) to account for missing data and as observed data (n/m (%), where n=number of patients with response and m=number of patients with evaluable data).</s><s>For continuous variables, mean change from baseline is reported as least-square mean change (SE) where mixed-effects model repeated measures analysis was performed and as observed data (SD).</s><s>Patients received a 10 mg/kg loading dose of secukinumab at baseline and weeks 2 and 4, before receiving indicated dose of secukinumab subcutaneously every four weeks from week 8. ASAS, Assessment of SpondyloArthritis international Society response criteria; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; hsCRP, high-sensitivity C-reactive protein; N/A, not available; SF-36 PCS, Short Form-36 physical component summary.</s></p></div></figDesc><table><row><cell></cell><cell>Imputed</cell><cell></cell><cell>Observed</cell><cell></cell></row><row><cell></cell><cell>Secukinumab</cell><cell>Secukinumab</cell><cell></cell><cell></cell></row><row><cell></cell><cell>intravenous 150 mg</cell><cell>intravenous 75 mg</cell><cell>Secukinumab</cell><cell>Secukinumab</cell></row><row><cell>Efficacy end point</cell><cell>(n=125)</cell><cell>(n=124)</cell><cell>intravenous 150 mg</cell><cell>intravenous 75 mg</cell></row><row><cell>ASAS20 response</cell><cell>73.7%</cell><cell>68.0%</cell><cell>69/87 (79.3%)</cell><cell>62/86 (72.1%)</cell></row><row><cell>ASAS40 response</cell><cell>55.7%</cell><cell>48.5%</cell><cell>56/87 (64.4%)</cell><cell>46/86 (53.5%)</cell></row><row><cell>hsCRP, median change from baseline</cell><cell>N/A</cell><cell>N/A</cell><cell>-4.20 (-143.6, 50.0)</cell><cell>-2.7 (-97.5, 30.2)</cell></row><row><cell>(min, max) (mg/L)</cell><cell></cell><cell></cell><cell>(n=88)</cell><cell>(n=87)</cell></row><row><cell>ASAS5/6 response</cell><cell>57.9%</cell><cell>52.2%</cell><cell>56/87 (64.4%)</cell><cell>49/86 (57.0%)</cell></row><row><cell>BASDAI, mean change from baseline</cell><cell>-2.93 (0.18)</cell><cell>-2.75 (0.18)</cell><cell>-3.41 (2.12)</cell><cell>-3.04 (1.81)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(n=87)</cell><cell>(n=86)</cell></row><row><cell>SF-36 PCS score, mean change from baseline</cell><cell>6.88 (0.68)</cell><cell>6.36 (0.69)</cell><cell>8.06 (8.08)</cell><cell>7.41 (6.83)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(n=87)</cell><cell>(n=85)</cell></row><row><cell>ASQoL score, mean change from baseline</cell><cell>-4.38 (0.45)</cell><cell>-4.34 (0.45)</cell><cell>-4.82 (4.83)</cell><cell>-4.58 (4.44)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(n=86)</cell><cell>(n=85)</cell></row><row><cell>ASAS partial remission</cell><cell>25.6%</cell><cell>19.3%</cell><cell>28/87 (32.2%)</cell><cell>20/86 (23.3%)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Baseline characteristics of the X-ray completer cohort randomised to secukinumab at baseline</s></p></div></figDesc><table><row><cell></cell><cell>Secukinumab</cell><cell>Secukinumab</cell></row><row><cell></cell><cell>intravenous</cell><cell>intravenous</cell></row><row><cell></cell><cell>150 mg</cell><cell>75 mg</cell></row><row><cell>Characteristic</cell><cell>(n=86)</cell><cell>(n=82)</cell></row><row><cell>Age, mean (SD) years</cell><cell>39.6 (12.0)</cell><cell>42.4 (13.1)</cell></row><row><cell>Male gender, n (%)</cell><cell>63 (73.3)</cell><cell>60 (73.2)</cell></row><row><cell>Weight, mean (SD) kg</cell><cell>75.2 (16.4)</cell><cell>78.4 (19.3)</cell></row><row><cell>Time since AS diagnosis, mean (SD)</cell><cell>6.6 (7.0)</cell><cell>7.8 (8.9)</cell></row><row><cell>years</cell><cell></cell><cell></cell></row><row><cell>HLA-B27 positive, n (%)</cell><cell>64 (74.4)</cell><cell>72 (87.8)</cell></row><row><cell>Current smoker, n (%)</cell><cell>25 (29.1)</cell><cell>17 (20.7)</cell></row><row><cell>Anti-TNF-naive, n (%)</cell><cell>60 (69.8)</cell><cell>62 (75.6)</cell></row><row><cell>Medication use at baseline, n (%)</cell><cell></cell><cell></cell></row><row><cell>Methotrexate</cell><cell>14 (16.3)</cell><cell>12 (14.6)</cell></row><row><cell>Sulfasalazine</cell><cell>27 (31.4)</cell><cell>32 (39.0)</cell></row><row><cell>Glucocorticoids</cell><cell>13 (15.1)</cell><cell>10 (12.2)</cell></row><row><cell>hsCRP, median (min, max), mg/L</cell><cell>7.8 (0.2, 147.7)</cell><cell>9.7 (0.4, 100.0)</cell></row><row><cell>Elevated hsCRP &gt;5 mg/L, n (%)</cell><cell>55 (64.0)</cell><cell>50 (61.0)</cell></row><row><cell>Total BASDAI, mean (SD)</cell><cell>6.2 (1.6)</cell><cell>6.0 (1.5)</cell></row><row><cell>BASFI, mean (SD)</cell><cell>5.6 (2.2)</cell><cell>5.4 (2.0)</cell></row><row><cell>BASMI (linear), mean (SD)</cell><cell>3.9 (1.8)</cell><cell>4.2 (1.7)</cell></row><row><cell>mSASSS, mean (SD)</cell><cell>9.6 (16.6)</cell><cell>10.8 (16.7)</cell></row><row><cell>Syndesmophyte present, n (%)</cell><cell>51 (59.3)</cell><cell>53 (64.6)</cell></row><row><cell>Total back pain, mean (SD)</cell><cell>63.9 (17.2)</cell><cell>63.3 (18.6)</cell></row><row><cell>Patient's global assessment of disease</cell><cell>64.6 (17.7)</cell><cell>60.5 (18.6)</cell></row><row><cell>activity, mean (SD)</cell><cell></cell><cell></cell></row><row><cell cols="2">Data are n (%), mean (SD), or median (minimum-maximum).</cell><cell></cell></row></table><note><p><s>AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; HLA, human leucocyte antigen; hsCRP, high-sensitivity C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; TNF, tumour necrosis factor.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 4</head><label>4</label><figDesc><div><p><s>Incidence of treatment-emergent adverse events (AEs) during the entire treatment period through to week 104 Includes patients randomised to secukinumab at baseline and patients who were randomised to placebo who switched to secukinumab at weeks 16 or 24.</s><s>†Reported as mean (SD).</s><s>‡Serious AEs also include deaths.</s><s>§Up to week 104; an additional two patients discontinued secukinumab due to any AEs after week 104.</s><s>¶System organ class category.</s></p></div></figDesc><table><row><cell></cell><cell>Any</cell><cell>Any</cell><cell>Any</cell></row><row><cell></cell><cell>secukinumab</cell><cell>secukinumab</cell><cell>secukinumab</cell></row><row><cell></cell><cell>150 mg</cell><cell>75 mg</cell><cell>pooled</cell></row><row><cell>Variable</cell><cell>(n=181)*</cell><cell>(n=179)*</cell><cell>(n=360)*</cell></row><row><cell>Exposure to study</cell><cell>621.3 (187.5)</cell><cell>642.0 (180.9)</cell><cell>631.6 (184.3)</cell></row><row><cell>treatment (days) †</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Number of patients with event (%)</cell><cell></cell><cell></cell></row><row><cell>Any AE</cell><cell>157 (86.7)</cell><cell>144 (80.4)</cell><cell>301 (83.6)</cell></row><row><cell>Serious AE ‡</cell><cell>22 (12.2)</cell><cell>24 (13.4)</cell><cell>46 (12.8)</cell></row><row><cell>Any AE leading to</cell><cell>17 (9.4)</cell><cell>8 (4.5)</cell><cell>25 (6.9)</cell></row><row><cell>discontinuation §</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Infection or</cell><cell>110 (60.8)</cell><cell>100 (55.9)</cell><cell>210 (58.3)</cell></row><row><cell>infestation ¶</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Common AEs (seen in &gt;5% of patients on secukinumab), n (%)</cell><cell></cell></row><row><cell>Nasopharyngitis</cell><cell>44 (24.3)</cell><cell>35 (19.6)</cell><cell>79 (21.9)</cell></row><row><cell>Diarrhoea</cell><cell>25 (13.8)</cell><cell>22 (12.3)</cell><cell>47 (13.1)</cell></row><row><cell>Headache</cell><cell>22 (12.2)</cell><cell>20 (11.2)</cell><cell>42 (11.7)</cell></row><row><cell>Upper respiratory tract</cell><cell>17 (9.4)</cell><cell>21 (11.7)</cell><cell>38 (10.6)</cell></row><row><cell>infection</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pharyngitis</cell><cell>21 (11.6)</cell><cell>12 (6.7)</cell><cell>33 (9.2)</cell></row><row><cell>Dyslipidaemia</cell><cell>14 (7.7)</cell><cell>16 (8.9)</cell><cell>30 (8.3)</cell></row><row><cell>Influenza</cell><cell>17 (9.4)</cell><cell>13 (7.3)</cell><cell>30 (8.3)</cell></row><row><cell>Oropharyngeal pain</cell><cell>16 (8.8)</cell><cell>13 (7.3)</cell><cell>29 (8.1)</cell></row><row><cell>Arthralgia</cell><cell>13 (7.2)</cell><cell>11 (6.1)</cell><cell>24 (6.7)</cell></row><row><cell>Back pain</cell><cell>13 (7.2)</cell><cell>7 (3.9)</cell><cell>20 (5.6)</cell></row><row><cell>Leucopenia</cell><cell>8 (4.4)</cell><cell>12 (6.7)</cell><cell>20 (5.6)</cell></row><row><cell>Cough</cell><cell>10 (5.5)</cell><cell>9 (5.0)</cell><cell>19 (5.3)</cell></row><row><cell>Nausea</cell><cell>10 (5.5)</cell><cell>9 (5.0)</cell><cell>19 (5.3)</cell></row><row><cell cols="4">AEs of special interest, n (exposure-adjusted incidence rate per 100 patient-years)</cell></row><row><cell>Candida infections</cell><cell>2 (0.7)</cell><cell>2 (0.6)</cell><cell>4 (0.7)</cell></row><row><cell>Serious infections</cell><cell>3 (1.0)</cell><cell>3 (1.0)</cell><cell>6 (1.0)</cell></row><row><cell>Crohn's disease</cell><cell>1 (0.3)</cell><cell>4 (1.3)</cell><cell>5 (0.8)</cell></row><row><cell>Major adverse cardiac</cell><cell>2 (0.7)</cell><cell>2 (0.6)</cell><cell>4 (0.6)</cell></row><row><cell>events (adjudicated)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Malignancy</cell><cell>3 (1.0)</cell><cell>1 (0.3)</cell><cell>4 (0.6)</cell></row><row><cell>Neutropenia</cell><cell>9 (3.1)</cell><cell>14 (4.8)</cell><cell>23 (3.9)</cell></row><row><cell>(preferred term)</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>mSASSS in the X-ray completer cohort randomised to secukinumab at baseline</s></p></div></figDesc><table><row><cell></cell><cell>Secukinumab</cell><cell>Secukinumab</cell><cell></cell></row><row><cell></cell><cell>intravenous</cell><cell>intravenous</cell><cell>Secukinumab</cell></row><row><cell>Variable</cell><cell>150 mg</cell><cell>75 mg</cell><cell>pooled</cell></row><row><cell>Overall population</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>86</cell><cell>82</cell><cell>168</cell></row><row><cell>Baseline</cell><cell>9.63 (16.63)</cell><cell>10.84 (16.69)</cell><cell>10.22 (16.62)</cell></row><row><cell>Change at</cell><cell>0.30 (1.94)</cell><cell>0.31 (3.04)</cell><cell>0.30 (2.53)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Patients with syndesmophytes at baseline</cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>51</cell><cell>53</cell><cell>104</cell></row><row><cell>Baseline</cell><cell>16.12 (19.09)</cell><cell>16.69 (18.32)</cell><cell>16.41 (18.61)</cell></row><row><cell>Change at</cell><cell>0.49 (2.50)</cell><cell>0.45 (3.77)</cell><cell>0.47 (3.20)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Patients without syndesmophytes at baseline</cell><cell></cell></row><row><cell>Patients (n)</cell><cell>35</cell><cell>29</cell><cell>64</cell></row><row><cell>Baseline</cell><cell>0.17 (0.56)</cell><cell>0.16 (0.40)</cell><cell>0.16 (0.49)</cell></row><row><cell>Change at</cell><cell>0.01 (0.19)</cell><cell>0.03 (0.33)</cell><cell>0.02 (0.26)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Elevated hsCRP</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>55</cell><cell>50</cell><cell>105</cell></row><row><cell>Baseline</cell><cell>11.57 (17.69)</cell><cell>14.22 (19.16)</cell><cell>12.83 (18.36)</cell></row><row><cell>Change at</cell><cell>0.48 (2.25)</cell><cell>0.46 (3.08)</cell><cell>0.47 (2.66)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal hsCRP</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>31</cell><cell>32</cell><cell>63</cell></row><row><cell>Baseline</cell><cell>6.18 (14.19)</cell><cell>5.56 (10.04)</cell><cell>5.87 (12.16)</cell></row><row><cell>Change at</cell><cell>-0.03 (1.16)</cell><cell>0.06 (3.00)</cell><cell>0.02 (2.27)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>63</cell><cell>60</cell><cell>123</cell></row><row><cell>Baseline</cell><cell>11.91 (18.57)</cell><cell>13.70 (18.44)</cell><cell>12.78 (18.45)</cell></row><row><cell>Change at</cell><cell>0.19 (2.01)</cell><cell>0.58 (3.44)</cell><cell>0.38 (2.79)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>23</cell><cell>22</cell><cell>45</cell></row><row><cell>Baseline</cell><cell>3.39 (6.44)</cell><cell>3.05 (5.68)</cell><cell>3.22 (6.02)</cell></row><row><cell>Change at</cell><cell>0.59 (1.73)</cell><cell>-0.46 (1.23)</cell><cell>0.08 (1.58)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Smokers (at baseline)</cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>25</cell><cell>17</cell><cell>42</cell></row><row><cell>Baseline</cell><cell>13.10 (19.45)</cell><cell>10.88 (9.20)</cell><cell>12.20 (16.00)</cell></row><row><cell>Change at</cell><cell>−0.18 (1.71)</cell><cell>1.56 (4.00)</cell><cell>0.52 (2.95)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Non-smokers (at baseline)</cell><cell></cell><cell></cell></row><row><cell>Patients (n)</cell><cell>61</cell><cell>65</cell><cell>126</cell></row><row><cell>Baseline</cell><cell>8.21 (15.28)</cell><cell>10.83 (18.21)</cell><cell>9.56 (16.84)</cell></row><row><cell>Change at</cell><cell>0.49 (2.00)</cell><cell>-0.02 (2.67)</cell><cell>0.23 (2.38)</cell></row><row><cell>week 104</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-209730 on 13 December 2016. Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The authors acknowledge Sarah E Warner, Senior Director of Scientific and Medical Services for PAREXEL International Medical Imaging, for her expert advice on imaging throughout the trial.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Contributors JB, JS, DB, XB, AD, PE, HBR, RM and SM were involved in the design of the study.</s><s>DB, AD, JS and JB enrolled subjects into the study.</s><s>All authors contributed to the analysis and interpretation of the data.</s></p><p><s>Funding This clinical trial was sponsored by Novartis Pharma AG.</s><s>Medical writing support was provided by Chris Strutynskyj-Stannard, Joanne Fitz-Gerald, and Rugina Ali from Seren Communications, an Ashfield company, part of UDG Healthcare plc, the funding for which was provided by Novartis.</s></p><p><s>Competing interests JB has received honoraria for talks, advisory boards, paid consultancies and grants for studies from Abbott/AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Janssen, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB.</s><s>XB has served as a consultant or paid speaker for or participated in clinical trials sponsored by AbbVie, Boehringer Ingelheim, Celgene, Centocor, Chugai, MSD, Novartis, Pfizer and UCB.</s><s>AD has received research grants and honorarium for serving on the advisory boards of AbbVie, Amgen, Boehringer Ingelheim, Janssen, Novartis, Pfizer and UCB.</s><s>DB has served as a consultant or paid speaker for or participated in clinical trials sponsored by AbbVie, BMS, Boehringer Ingelheim, Glenmark, Janssen, Eli Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Roche and UCB.</s><s>JS has served as a consultant or paid speaker for or participated in clinical trials sponsored by AbbVie, Janssen, Eli Lilly, Merck, Novartis, Pfizer and UCB.</s><s>PE has participated in clinical trials for and provided expert advice to AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, Roche, Samsung, Takeda and UCB.</s><s>AR, RM and HBR are employees of Novartis.</s><s>AR and HBR own Novartis stock.</s></p><p><s>Patient consent Obtained.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p><s>The study was conducted in accordance with Good Clinical Practice and the principles of the Declaration of Helsinki.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Data sharing statement A copy of the study protocol is available on request from the study sponsors.</s></p><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http://creativecommons.org/ licenses/by-nc/4.0/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Downloaded from REFERENCES</title>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-209730on13</idno>
		<imprint>
			<date type="published" when="2016-12">December 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Ankylosing spondylitis: a state of the art factual backbone</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ghasemi-Rad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Attaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lesha</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Radiol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="236" to="252" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Baeten</surname></persName>
		</author>
		<author>
			<persName><surname>Spondyloarthritis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="2127" to="2137" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sieper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudwaleit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="1" to="44" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="896" to="904" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deodhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheumatol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="282" to="298" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kivitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Schiff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="2136" to="2146" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Davis</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="3230" to="3236" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Inman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Davis</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="3402" to="3412" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dijkmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Geusens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="582" to="591" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deodhar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="39" to="47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Emerging drugs for the treatment of axial and peripheral spondyloarthritis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kiltz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Heldmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Emerg Drugs</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome</title>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fritz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1690" to="1699" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Hermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1107" to="1113" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Salonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Weissman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">R127</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="3063" to="3070" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Einstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1324" to="1331" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response</title>
		<author>
			<persName><forename type="first">H</forename><surname>Appel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">R95</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bowness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ridley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="2672" to="2680" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Delay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Klenk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="2633" to="2643" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats</title>
		<author>
			<persName><forename type="first">S</forename><surname>Glatigny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Blaton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="110" to="120" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Duan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1420" to="1429" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Noordenbos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yeremenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gofita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="99" to="109" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sarin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Abraham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="9560" to="9565" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Goodall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hill</forename><surname>Gaston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1647" to="1656" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8− entheseal resident T cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Sherlock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Joyce-Shaikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Turner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1069" to="1076" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">Anti-IL-17A treatment blocks inflammation, destruction and new bone formation in experimental spondyloarthritis in HLA-B27</title>
		<author>
			<persName><forename type="first">M</forename><surname>Van Tok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Van Duivenvoorde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kramer</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>transgenic rats [abstract</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">17a-treatment-blocks-inflammation-destruction-andnew-bone-formation-in-experimental-spondyloarthritis-in-hla-b27-transgenic-rats</title>
		<ptr target="http://acrabstracts.org/abstract/anti-il-" />
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheumatol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">22</biblScope>
			<date type="published" when="2015-12">2015. Dec 2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Adamopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autoimmunity</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="243" to="252" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Adamopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Geissler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">R29</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Koenders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lubberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oppers-Walgreen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="141" to="149" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Secukinumab in plaque psoriasisresults of two phase three trials</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Langley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Elewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lebwohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="326" to="328" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mease</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Mcinnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kirkham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1329" to="1332" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">on behalf of the MEASURE 1 and MEASURE 2 Study Groups. Secukinumab interleukin-17A inhibition in ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Baeten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sieper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="2534" to="2548" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index</title>
		<author>
			<persName><forename type="first">S</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jenkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Kennedy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2286" to="2291" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">How to score Version Two of the SF-36 Health Survey</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Ware</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kosinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Dewey</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>Quality Metric</publisher>
			<pubPlace>Lincoln, RI</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Doward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spoorenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Cook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="20" to="26" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Creemers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Franssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van't Hof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="127" to="129" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes</title>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudwaleit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="910" to="915" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">Common Terminology Criteria for Adverse Events (CTCAE) version 4</title>
		<ptr target="http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf" />
		<imprint>
			<date type="published" when="2010-06">June 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Immunogenicity of the novel anti-il-17a antibody, secukinumab, with intravenous and subcutaneous dosing regimens in healthy subjects and patients</title>
		<author>
			<persName><forename type="first">U</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vogel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">630</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Haroon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Inman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Learch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="2645" to="2654" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haibel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="710" to="715" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Poddubnyy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haibel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1388" to="1398" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sieper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Poddubnyy</surname></persName>
		</author>
		<imprint>
			<publisher>ENRADAS</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1438" to="1443" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Puel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cypowyj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bustamante</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="page" from="65" to="68" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mathieu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="557" to="563" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Correlations between psoriasis and inflammatory bowel diseases</title>
		<author>
			<persName><forename type="first">N</forename><surname>Skroza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Proietti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pampena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">983902</biblScope>
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A protective function for interleukin 17A in T cell-mediated intestinal inflammation</title>
		<author>
			<persName><surname>O'connor W Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kamanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Booth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="603" to="609" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baraliakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="639" to="647" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Der Linden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1979" to="1985" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
